What is claimed is:

1. A scaffold of Formula (II):


$$A^{1'}\text{-}(L^C)_{0 \text{ or } 1}\text{-}D \text{ (II)}$$

or a pharmaceutically acceptable salt or solvate thereof, wherein:

L^C is a linker unit;

$A^{1'}$ is a monovalent linker moiety comprising a functional group capable of forming a covalent bond with a functional group of a PBRM, wherein PBRM denotes a protein-based recognition-molecule;

D is a compound of Formula (A):



(A)

or a prodrug, solvate, pharmaceutically acceptable salt, or tautomer thereof, wherein:

Y_1, Y_2, Z_1 and Z_2 are each independently O, S, C or N;

X_1, X_2, W_1 and W_2 are each independently C or N;

X_3 and X_4 are each independently S or NR^f;

X_5 is N or CR^{A2};

X_6 is N or CR^{A1};

R^3 and R^5 are each independently $-CON(R^d)(R^f)$, $-CH_2N(R^d)(R^f)$, $-N(R^d)(R^f)$, $-N(R^d)CO(R^f)$, $-CH_2N(R^d)CO(R^f)$ or one of R^3 and R^5 is $-CON(R^d)(R^f)$, $-CH_2N(R^d)(R^f)$, $-N(R^d)(R^f)$, $-N(R^d)CO(R^f)$ or $-CH_2N(R^d)CO(R^f)$, and the other of R^3 and R^5 is H, -COOH, or $-CO_2(R^C)$;

R^c is $C_{1\text{-}4}$ alkyl;

R^{A2} and R^{A1} are each independently H, halogen, hydroxy, amino, amino($C_{1\text{-}4}$ alkyl)-,

optionally substituted (C_{1-6} alkyl), or optionally substituted (C_{1-6} alkyl)oxy-, wherein C_{1-6} alkyl of said optionally substituted (C_{1-6} alkyl), or optionally substituted (C_{1-6} alkyl)oxy- is optionally substituted with 1-4 substituents each independently selected from the group comprising hydroxyl, C_{1-4} alkoxyl, -N(R^e)(R^f), -CO_2(R^f), -CON(R^e)(R^f), and -COOH;

each R^d is independently H, hydroxy, or C_{1-4} alkyl;

R^e is selected from H, (C_{1-4} alkyl), -CO(C_{1-4} alkyl), -OCO(C_{1-4} alkyl), and -CO_2(C_{1-4} alkyl);

each R^f is independently H, hydroxy, or (C_{1-4} alkyl);


R^{14} and R^{C2} are each independently absent or C_{1-4} alkyl, wherein C_{1-4} alkyl is optionally substituted by a substituent selected from halogen, -OR^c, -NR^cR^d, -CO_2R^c, -$CONR^cR^d$, -$SO_2NR^cR^d$, and -$OCONR^cR^d$;

R^{16} and R^{C1} are each independently absent, H or C_{1-4} alkyl; and

R^{15}, R^{17}, R^{18}, or R^{19} are each independently absent, H, or C_{1-4} alkyl, wherein C_{1-4} alkyl is optionally substituted by a substituent selected from halogen, -OR^c, -NR^cR^d, -CO_2R^c, -$CONR^cR^d$, -$SO_2NR^cR^d$, and -$OCONR^cR^d$;

wherein: (i) at least one of R^{A2} and R^{A1} is present, and wherein at least one of R^{A2} and R^{A1} is directly or indirectly connected to L^C, or to A^1 when L^C is absent, via at least one functional group of the R^{A2} and/or R^{A1}; or (ii) at least one of R^{C2} and R^{C1} is present, and wherein at least one of R^{C2} and R^{C1} is directly or indirectly connected to L^C, or to A^1 when L^C is absent, via at least one functional group of the R^{C2} and/or R^{C1}.

2. The scaffold of claim 1, wherein the scaffold is:



3. The scaffold of claim 1, further comprising a PBRM, thereby forming a conjugate.

4. The conjugate of claim 3 wherein PBRM is an antibody.

5. The conjugate of claim 3 or 4, wherein the conjugate is of Formula (I):

$$\text{PBRM-}[A^1\text{-}(L^C)_{0 \text{ or } 1}\text{-D}]_{d15} \quad \text{(I)}$$


or a pharmaceutically acceptable salt or solvate thereof,

A^1 is a divalent linker moiety connecting the PBRM to L^C, or to D when L^C is absent;

d_{15} is an integer from about 1 to about 20.

6. The conjugate of any one of claims 3-5, wherein the PBRM is XMT-1519.


7. The conjugate of any one of claims 3-5, wherein when PBRM is XMT-1519, D is not




,

wherein R^2 is -O-; and $-\S-$ denotes attachment to L^C or to A^1 when L^C is absent.


8. The conjugate of any one of claims 3-5, wherein when PBRM is XMT-1519, D independently is:




;




;





;





;



;



;



;








;



;



;



;



;



;

;

;

;

;

;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;










;










;



;



;



;



;

;

;

;

;

;

;

;



;

;

;

;

;

;

;

;



;



;



;






;


;


;


;


;


;

;

;
or

;



wherein:


R^2 is absent, -O- or -NR^4-;


R^4 is H or C_{1-3} alkyl; and


 denotes attachment to L^C or to A^1 when L^C is absent.


9. The conjugate of any one of claims 3-5, wherein when PBRM is not XMT-1519, D independently is:



;

;



;



;



;



;



;



;



;



;



;










;



;



;



;



;



;

;

;

;

;

;

;

;



;



;



;



;



;



;



;



;



;



;



;










;



;



;



;



;



;

;

;

;

;

;

;

;



;



;



;










;










;



;



;



;



;

;

;

;

;

;

;

;



;

;

;

;

;

;

;

;



;



;



;



;



;



;


;



;


;


;


;

or


;


wherein:

R^2 is absent, -O- or -NR^4-;

R^4 is H or C_{1-3} alkyl; and


 denotes attachment to L^C or to A^1 when L^C is absent;

10. The conjugate of any one of claims 3-5, wherein the conjugate of Formula (I) is not:



.

11. The conjugate or scaffold of any one of the preceding claims, wherein each L^C independently is



wherein:


# denotes attachment to A^1 and ## denotes attachment to D;

M^A is a peptide moiety comprising at least two amino acids;

T^1 is a hydrophilic group;

L^D is a divalent linker moiety connecting D to M^A, or D to A^1 when M^A is absent.





12. The conjugate of any one of claims 3-11, being of Formula (I-B'):



(I-B')

or a pharmaceutically acceptable salt or solvate thereof.

13. The conjugate or scaffold of any one of the preceding claims, wherein each A^1 independently is:


; 
; 
; or 
,

wherein:

R^7 is -O-, -NR^8, -(C_1-C_{10} alkyl)-, -(C_1-C_{10} alkenyl)-, -(C_1-C_{10} alkynyl)-, -(C_3-C_8 cycloalkyl)-, -aryl-, -O-(C_1-C_8 alkyl)-, -O-(C_1-C_{10} alkenyl)-, -O-(C_1-C_{10} alkynyl)-, -(C_1-C_{10} alkyl)-(C_3-C_8 cycloalkyl)-, -(C_1-C_{10} alkyl)-aryl-, -(C_2-C_{10} alkenyl)-(C_3-C_8 cycloalkyl)-, -(C_2-C_{10} alkenyl)-aryl-, -




(C_2-C_{10} alkynyl)-(C_3-C_8 cycloalkyl)-, -(C_2-C_{10} alkynyl)-aryl-, -(C_3-C_8 cycloalkyl)-(C_1-C_{10} alky)-, -aryl-(C_1-C_{10} alky)-, -(C_3-C_8 cycloalkyl)-(C_2-C_{10} alkenyl)-, -aryl-(C_2-C_{10} alkenyl)-, -(C_3-C_8 cycloalkyl)-(C_2-C_{10} alkynyl)-, -aryl-(C_2-C_{10} alkynyl)-, -(3- to 8-membered heterocycloalkyl)-, -(5- to 8-membered heteroaryl)-, -(C_1-C_{10} alkyl)-(3- to 8-membered heterocycloalkyl)-, -(C_1-C_{10} alkyl)-(5- to 8-membered heteroaryl)-, -(C_2-C_{10} alkenyl)-(3- to 8-membered heterocycloalkyl)-, -(C_2-C_{10} alkenyl)-(5- to 8-membered heteroaryl)-, -(C_2-C_{10} alkynyl)-(3- to 8-membered heterocycloalkyl)-, -(C_2-C_{10} alkynyl)-(5- to 8-membered heteroaryl)-, -(3- to 8-membered heterocycloalkyl)-(C_1-C_{10} alkyl)-, -(5- to 8-membered heteroaryl)-(C_1-C_{10} alkyl)-, -(3- to 8-membered heterocycloalkyl)-(C_2-C_{10} alkenyl)-, -(5- to 8-membered heteroaryl)-(C_2-C_{10} alkenyl)-, -(5- to 8-membered heteroaryl)-(C_2-C_{10} alknyl)-, -(5- to 8-membered heteroaryl)-(C_2-C_{10} alknyl)-, -O-C(O)-$(CH_2CH_2O)_r$-$(CH_2)_2$-, -$(CH_2CH_2O)_r$-, or -$(CH_2CH_2O)_r$-$(CH_2)_2$-, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, aryl, heterocycloalkyl, or heteroaryl is optionally substituted;


R^8 is H, hydroxy, or $C_{1\text{-}4}$ alkyl;

r is an integer ranging from about 1 to about 12; and

* denotes attachment to PBRM and ** denotes attachment to L^C, or to D when L^C is absent.

14. The scaffold of claim 1, wherein each $A^{1'}$ independently is:



;

;

;

or

;

wherein:

r is an integer ranging from about 4 to about 6; and

** denotes attachment to L^C, or to D when L^C is absent.

15. The conjugate or scaffold of any one of the preceding claims, wherein each L^D independently is , wherein:

L^E is -NH-[$(CH_2CH_2O)_p$-$(CH_2)_{0-2}$]$_q$-C(O)-, -NH-(C_1-C_6 alkyl)-O-C(O)-, or -NH-[$(CH_2CH_2O)_p$-$(CH_2)_{0-2}$]$_q$-C(O)-NH-(C_1-C_6 alkyl)-O-C(O)-, wherein p is an integer ranging from about 1 to about 20, and q is an integer ranging from about 1 to about 10;

each W independently is a natural or unnatural amino acid unit;

w is an integer ranging from about 0 to about 12;


*** denotes attachment to M^A, or to A^1 when M^A is absent; and


**** denotes attachment to D.


16. The conjugate or scaffold of claim 15, wherein w is 0, 1, 2, 3, 4, or 5.


17. The conjugate or scaffold of claim 15 or 16, wherein L^E is -NH-$(CH_2CH_2O)_2$-$(CH_2)_2$-C(O)-, -NH-CH_2-$CH(CH_3)$-O-C(O)-, or -NH-[$(CH_2CH_2O)_{1-4}$-$(CH_2)_2$-C(O)-NH-$(CH_2)_2$-O-C(O)-.


18. The conjugate or scaffold of any one of the preceding claims, wherein each L^D independently is:


(1) ;


(2) ;


(3) ;


(4) ;


(5) ;


(6) ;


(7)  ;


(8)  ;


(9)  ;


(10)  ;


(11)  ;


(12)  ;


(13)  ;


(14)  ;


(15)  ;


(16)  ;


(17)  ;


(18)  ;


(19)  ;


(20)  ;


(21)  ;


(22)  ;


(23)  ;


(24)  ;


(25)  ;


(26)  ;


(27)  ;


(28)  ;


(29)  ;


(30)  ;

(31)  ;

(32)  ;


(33)  ;


(34)  ; or



(35)  ;



wherein: *** denotes attachment to M^A, or to A^1 when M^A is absent; and **** denotes attachment to D.


19. The conjugate or scaffold of any one of the preceding claims, wherein L^D is:

(1)  ;

(2)  ;


(3)  ; (4)  ;

(5)  ; (6)  ;or

(7)  ;

wherein: *** denotes attachment to M^A, or to A^1 when M^A is absent; and **** denotes attachment to D.


20. The conjugate or scaffold of any one of the preceding claims, wherein L_D is

 , wherein:

*** denotes attachment to M^A, or to A^1 when M^A is absent; and

**** denotes attachment to D.

21. The conjugate or scaffold of any one of the preceding claims, wherein M^A is

 ,

wherein: * indicates attachment to A^1; ** indicates attachment to T^1; and *** indicates attachment to L^D.

22. The conjugate or scaffold of any one of the preceding claims, wherein T^1 is –OH or $-\overset{\S}{\underset{\S}{}}NH-R_{60}-(CR_{58}OH)_{n1}-R_{61}$, wherein:

n_1 is an integer from 0 to about 6;

each R_{58} is independently -H or C_{1-8} alkyl;



R_{60} is a bond, a C_{1-6} alkyl linker, or $–CHR_{59}$- wherein R_{59} is -H, C_{1-8} alkyl, cycloalkyl, or arylalkyl;

R_{61} is CH_2OR_{62}, $COOR_{62}$, $-(CH_2)_{n2}COOR_{62}$, or a heterocycloalkyl substituted with one or more hydroxyl;


R_{62} is -H or C_{1-8} alkyl; and

n_2 is an integer from 1 to about 5.

23. The conjugate or scaffold of any one of the preceding claims, wherein T^1 is


or

.

24. The conjugate or scaffold of any one of the preceding claims, wherein T^1 is


, wherein







n_4 is an integer from 1 to about 25;

each R_{63} is independently hydrogen or C_{1-8} alkyl;

R_{64} is a bond or a C_{1-8} alkyl linker;


R_{65} is H, C_{1-8} alkyl, $-(CH_2)_{n2}COOR_{62}$ or $-(CH_2)_{n2}COR_{66}$;

R_{62} is H or C_{1-8} alkyl;

R_{66} is H, 
, 
, 
, 
, 
, or 
; and







n_2 is an integer from 1 to about 5.

25. The conjugate or scaffold of any one of the preceding claims, wherein T^1 is:



,

wherein R_{67} is:(1) -OH;

(2)  ;	(3)  ;
(4)  ;	(5)  ;
(6)  ; or	(7) 

wherein n_4 is an integer from about 2 to about 20, from about 4 to about 16, from about 6 to about 12, from about 8 to about 12.







26. The conjugate or scaffold of claim 25, wherein n_4 is 6, 7, 8, 9, 10, 11, or 12.







27. The conjugate of any one of claims 4-13 and 15-26, wherein d_{15} is an integer from about 2 to about 8.


28. The conjugate of any one of claims 4-13 and 15-27, wherein d_{15} is 6 or 8.

29. The conjugate of any one of claims 4-13 and 15-28, wherein d_{15} is 8.


30. The conjugate or scaffold of any one of the preceding claims, wherein each D independently is of Formula (A-a), (A-b), (A-c), (A-d), (A-e), (A-f), (A-f1), (A-f2), (A-f)3, (A-f4), (A-f5), (A-g), (A-g1), (A-g2), (A-g3), (A-g4), (A-g5), (A-h), (A-h1), (A-h2), or (A-i):

 (A-a)	 ; (A-b)
 ; (A-c)	 ; (A-d)
 ; (A-e)	 ; (A-f)


 ; (A-f1)	 ; (A-f2)
 ; (A-f3)	 ; (A-f4)
 ; (A-f5)	 ; (A-g)


;


(A-g1)


;


(A-g2)


;


(A-g3)


;




(A-g4)


;

(A-g5)


;

(A-h)


<table>
<tr>
<td>
;
(A-h1)</td>
<td>
, or
(A-h2)</td>
</tr>
<tr>
<td>
,
(A-i)</td>
<td></td>
</tr>
</table>

or a prodrug, solvate, pharmaceutically acceptable salt, or tautomer thereof.


31. The scaffold of any one of the preceding claims, wherein the scaffold is selected from the scaffolds described in Table A1.

32. The scaffold of any one of the preceding claims, wherein the scaffold is selected from the scaffolds described in Table A2.

33. The scaffold of any one of the preceding claims, wherein the scaffold is:



or




.


34. The conjugate of any one of claims 4-14 and 16-30, selected from the conjugates described in Table B1.

35. The conjugate of any one of claims 4-14 and 16-30, selected from the conjugates described in Table B2.


36. The conjugate of any one of claims 4-14, 16-30, and 34-35, being


PBRM
S
d15


;



PBRM
d15


;



PBRM
S
d15

;



PBRM
S
O
N
H
OH
H_2N
X_3
X_6
X_4
R^{14}
Z_1
Y_1
R^{19}
W_1
X_1
R^{15}
R^{C1}
R^{C2}
Z_2
Y_2
R^{18}
W_2
X_2
R^{17}
R^{16}
d_{15}
;


PBRM
S
HO
O
N
H
H_2N
X_3
X_6
X_4
R^{14}
Z_1
Y_1
R^{19}
W_1
X_1
R^{15}
R^{C1}
R^{C2}
Z_2
Y_2
R^{18}
W_2
X_2
R^{17}
R^{16}
d_{15}
;



PBRM
S
O
N
H
OH
H_2N
X_3
X_6
X_4
R^{14}
Z_1
Y_1
R^{19}
W_1
X_1
R^{15}
R^{C1}
R^{C2}
Z_2
Y_2
R^{18}
W_2
X_2
R^{17}
R^{16}
d_{15}
; or


PBRM
S
HO
O
N
H
H_2N
X_3
X_6
X_4
R^{14}
Z_1
Y_1
R^{19}
W_1
X_1
R^{15}
R^{C1}
R^{C2}
Z_2
Y_2
R^{18}
W_2
X_2
R^{17}
R^{16}
d_{15}
.

37. The conjugate of any one of claims 4-14, 16-30, and 34-35, being





; or




.


38. The conjugate of any one of claims 4-14, 16-30, and 34-35, being



PBRM
S
NH2
OH
HO
d_{15}



PBRM
S
NH2
OH
HO
d_{15}


;


PBRM
S
NH2
OH
HO
NH
HN
O
N
d15
;



PBRM
S
NH2
OH
HO
NH
HN
O
N
d15


PBRM
S
HO
NH2
HN
O
N
d15
;


PBRM
S
HO
NH2
HN
O
N
d15
;



; or



.

39. A pharmaceutical composition comprising the conjugate of any one of claims 4-14, 16-30, and 34-38 and one or more pharmaceutically acceptable carriers or excipients.

40. The pharmaceutical composition comprising the conjugate of claim 39 further comprising at least one immuno-modulator or at least one immunostimulatory agent.

41. A method of activating or enhancing an activity of a stimulator of interferon genes (STING) in a subject, comprising administering to the subject the conjugate of any one of claims 4-14, 16-30, and 34-38, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 39 or claim 40.

42. A method of preventing or treating a disease or disorder in a subject, comprising administering to the subject the conjugate of any one of claims 4-14, 16-30, and 34-38, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 39 or claim 40.

43. The conjugate of any one of claims 4-14, 16-30, and 34-38, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 39 or claim 40, for activating or enhancing an activity of a stimulator of interferon genes (STING) in a subject.

44. The conjugate of any one of claims 4-14, 16-30, and 34-38, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 39 or claim 40, for preventing or treating a disease or disorder in a subject.

45. Use of any one of claims 4-14, 16-30, and 34-38, or a pharmaceutically acceptable salt

thereof, or a pharmaceutical composition of claim 39 or claim 40, in the manufacture of a medicament for activating or enhancing an activity of a stimulator of interferon genes (STING) in a subject.

46. Use of any one of claims 4-14, 16-30, and 34-38, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of claim 39 or claim 40, in the manufacture of a medicament for preventing or treating a disease or disorder in a subject.

47. The method, conjugate for use, or use of any one of claims 41-46, wherein the disease or disorder is associated with the agonism of STING.

48. The method, conjugate for use, or use of any one of claims 41-47, wherein the disease or disorder is cancer.

49. The method, conjugate for use, or use of any one of claims 41-48, wherein the disease or disorder is bladder cancer, breast cancer, colorectal cancer, colon cancer, endometrial cancer, gastric cancer, head and neck squamous carcinoma, melanoma, lung cancer, ovarian cancer, esophageal cancer, biliary cancer, urothelial cancer, cervical cancer, papillary thyroid cancer, papillary renal cell cancer, cholangiocarcinoma, salivary duct cancer, kidney cancer, or pancreatic cancer.

50. A method of making an antibody-drug conjugate of Formula (I):

$$\text{PBRM-}[A^1\text{-}(L^C)_{0 \text{ or } 1}\text{-D}]_{d15} \quad \text{(I)}$$

or a pharmaceutically acceptable salt or solvate thereof,

A^1 is a divalent linker moiety connecting the PBRM to L^C, or to D when L^C is absent;

d_{15} is an integer from about 1 to about 20,

the method comprising:

(1) providing in solution the polymeric scaffold of Formula (II):


$$A^{1'}\text{-}(L^C)_{0 \text{ or } 1}\text{-D} \quad \text{(II)}$$

or a pharmaceutically acceptable salt or solvate thereof, wherein:

L^C is a linker unit;

$A^{1'}$ is a monovalent linker moiety comprising a functional group capable of forming a covalent bond with a functional group of a PBRM, wherein PBRM denotes a protein-based recognition-molecule;

D is a compound of Formula (A):



(A)

or a prodrug, solvate, pharmaceutically acceptable salt, or tautomer thereof, wherein:

Y_1, Y_2, Z_1 and Z_2 are each independently O, S, C or N;

X_1, X_2, W_1 and W_2 are each independently C or N;

X_3 and X_4 are each independently S or NR^f;

X_5 is N or CR^{A2};

X_6 is N or CR^{A1};

R^3 and R^5 are each independently $-CON(R^d)(R^f)$, $-CH_2N(R^d)(R^f)$, $-N(R^d)(R^f)$, $-N(R^d)CO(R^f)$, $-CH_2N(R^d)CO(R^f)$ or one of R^3 and R^5 is $-CON(R^d)(R^f)$, $-CH_2N(R^d)(R^f)$, $-N(R^d)(R^f)$, $-N(R^d)CO(R^f)$ or $-CH_2N(R^d)CO(R^f)$, and the other of R^3 and R^5 is H, -COOH, or $-CO_2(R^C)$;

R^c is $C_{1\text{-}4}$ alkyl;

R^{A2} and R^{A1} are each independently H, halogen, hydroxy, amino, amino($C_{1\text{-}4}$ alkyl)-, optionally substituted ($C_{1\text{-}6}$ alkyl), or optionally substituted ($C_{1\text{-}6}$ alkyl)oxy-, wherein $C_{1\text{-}6}$ alkyl of said optionally substituted ($C_{1\text{-}6}$ alkyl), or optionally substituted ($C_{1\text{-}6}$ alkyl)oxy- is optionally substituted with 1-4 substituents each independently selected from the group comprising hydroxyl, $C_{1\text{-}4}$ alkoxyl, $-N(R^e)(R^f)$, $-CO_2(R^f)$, $-CON(R^e)(R^f)$, and -COOH;

each R^d is independently H, hydroxy, or $C_{1\text{-}4}$ alkyl;

R^e is selected from H, (C_{1-4} alkyl), -CO(C_{1-4} alkyl), -OCO(C_{1-4} alkyl), and -CO_2(C_{1-4} alkyl);

each R^f is independently H, hydroxy, or (C_{1-4} alkyl);

R^{14} and R^{C2} are each independently absent or C_{1-4} alkyl, wherein C_{1-4} alkyl is optionally substituted by a substituent selected from halogen, -OR^c, -NR^cR^d, -CO_2R^c, -$CONR^cR^d$, -$SO_2NR^cR^d$, and -$OCONR^cR^d$;

R^{16} and R^{C1} are each independently absent, H or C_{1-4} alkyl; and

R^{15}, R^{17}, R^{18}, or R^{19} are each independently absent, H, or C_{1-4} alkyl, wherein C_{1-4} alkyl is optionally substituted by a substituent selected from halogen, -OR^c, -NR^cR^d, -CO_2R^c, -$CONR^cR^d$, -$SO_2NR^cR^d$, and -$OCONR^cR^d$;

wherein: (i) at least one of R^{A2} and R^{A1} is present, and wherein at least one of R^{A2} and R^{A1} is directly or indirectly connected to L^C, or to A^1 when L^C is absent, via at least one functional group of the R^{A2} and/or R^{A1}; or (ii) at least one of R^{C2} and R^{C1} is present, and wherein at least one of R^{C2} and R^{C1} is directly or indirectly connected to L^C, or to A^1 when L^C is absent, via at least one functional group of the R^{C2} and/or R^{C1}; and

(2) adding an activated PBRM to the solution comprising the polymeric scaffold of Formula (II), or a pharmaceutically acceptable salt or solvate thereof, to form the antibody-drug conjugate of Formula (I).